Article Text

Download PDFPDF

O-098 Potentially Harmful Excipients In Medicines Prescribed In Neonatal Intensive Care Units (nicu) – Product Substitution As A Way Forward
  1. G Nellis1,
  2. I Lutsar2,
  3. H Varendi1,
  4. J Lass3,
  5. MA Turner4,
  6. T Metsvaht5
  1. 1Neonatal Unit, Children`s Clinic of Tartu University Hospital, Tartu, Estonia
  2. 2Department of Microbiology, Tartu University, Tartu, Estonia
  3. 3Pharmacy Department, Tartu University Hospital, Tartu, Estonia
  4. 4Neonatal Unit, Liverpool Women`s Hospital, Liverpool, UK
  5. 5Paediatric Intensive Care Unit, Tartu University, Hospital, Tartu, Estonia


Background Excipients are essential for many medicines. Some have been associated with significant consequences in neonates. We aimed to identify substitution possibilities among medicines used in European neonates in order to minimise the administration of potentially harmful excipients of interest (EOI).

Methods A 3-day survey recording all medicines prescribed to neonates was performed in European NICUs. Based on existing toxicity data in neonates the EOI included parabens, polysorbate 80, propylene glycol, benzoates, saccharin sodium, sorbitol, ethanol and benzalkonium chloride. Opportunities for product substitution were defined as EOI-containing formulations for which an EOI-free product was reported in the survey with identical active pharmaceutical ingredient (API), galenic form and strength.

Results Of 31 invited European countries 20 with 115 NICUs responded. A total of 564 trade names (TN) with 53 APIs were used in more than 10% of units. EOI containing formulations (n = 151) were used for 31 APIs, found overall in 363 TNs. Compared to parenteral forms (50/199; 25%), enteral (83/130; 64%) and topical TNs (18/34; 53%) contained EOI more frequently (OR; 95% CI 5.3; 3.3–8.5 and 3.4; 1.6–7.1, respectively). An EOI free substitution was available for 31/50 parenteral (63%), 17/83 enteral (21%) and 3/18 topical (17%) TNs. Overall, 51/151 (34%) TNs with EOI could be replaced; substitution was possible in 92/151 (61%) of cases if the requirement for identical API strength was ignored.

Conclusions EOI-free formulations available on the European market could be used to reduce the number of TNs with EOI by at least a third.

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.